Choosing First-Line TKI Therapy for CML: Expert Approaches to Risk Assessment & Treatment Selection

Panelists discuss how in selecting first-line therapy for patients with newly diagnosed chronic myeloid leukemia, clinicians must carefully weigh factors including the patient’s risk score, comorbidities, drug interaction potential, monitoring requirements, and cost considerations while recognizing that available tyrosine kinase inhibitor options (imatinib, nilotinib, dasatinib, and bosutinib) have similar efficacy but distinct safety and tolerability profiles.

EP: 1.Evaluating Early Treatment Response in CML: Expert Insights on Monitoring

EP: 2.Interpreting Milestones: Prioritizing the Patient Picture

EP: 3.Managing T315I Mutations in CML: Second Line Treatment Options - Ponatinib & Asciminib

EP: 4.Beyond T315I mutations: When to Consider Ponatinib or Asciminib in CML Second-Line Treatment

EP: 5.Managing Adverse Events: Ponatinib & Asciminib in CML: Expert Approaches

Now Viewing

EP: 6.Choosing First-Line TKI Therapy for CML: Expert Approaches to Risk Assessment & Treatment Selection

Video content above is prompted by the following:

• How do you choose between these therapies when assessing a patient newly diagnosed with chronic myeloid leukemia?
• Please comment on any similarities or differences in your clinical practice when selecting between the first-line therapy options.

Related Videos